

Andri Rauch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/142288/publications.pdf>

Version: 2024-02-01

171
papers

8,138
citations

57758

44
h-index

56724

83
g-index

185
all docs

185
docs citations

185
times ranked

10237
citing authors

#	ARTICLE	IF	CITATIONS
1	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	1.9	69
2	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. <i>Scientific Reports</i> , 2022, 12, 577.	3.3	27
3	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e585-e593.	5.8	26
4	Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. <i>HIV Medicine</i> , 2022, 23, 849-858.	2.2	57
5	An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters. <i>Viruses</i> , 2022, 14, 784.	3.3	2
6	Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program. <i>Clinical Infectious Diseases</i> , 2022, 75, 1723-1731.	5.8	14
7	A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, , .	4.0	3
8	Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000945.	2.7	2
9	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021, 106, 2233-2241.	3.5	4
10	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2194-e2202.	5.8	47
11	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2021, 72, 2175-2183.	5.8	10
12	Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. <i>Liver International</i> , 2021, 41, 710-719.	3.9	15
13	Hepatitis C among men who have sex with men: knowing your epidemic. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 5-6.	8.1	5
14	Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. <i>Aids</i> , 2021, 35, 869-882.	2.2	27
15	The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , 2021, 11, 4586.	3.3	8
16	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	3.9	66
17	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. <i>Journal of Hepatology</i> , 2021, 75, 829-839.	3.7	27
18	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 295.	2.4	11

#	ARTICLE	IF	CITATIONS
19	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. <i>Trials</i> , 2021, 22, 724.	1.6	9
20	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. <i>PLoS Computational Biology</i> , 2021, 17, e1009529.	3.2	6
21	How do healthcare providers construe patient complexity? A qualitative study of multimorbidity in HIV outpatient clinical practice. <i>BMJ Open</i> , 2021, 11, e051013.	1.9	4
22	Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 Among Human Immunodeficiency Virus-positive Gay and Bisexual Men?. <i>Clinical Infectious Diseases</i> , 2020, 70, 106-113.	5.8	11
23	Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017. <i>HIV Medicine</i> , 2020, 21, 228-239.	2.2	46
24	Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. <i>Aids</i> , 2020, 34, 1485-1495.	2.2	3
25	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 517-524.	2.1	7
26	Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. <i>Aids</i> , 2020, 34, 1699-1711.	2.2	21
27	2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. <i>HIV Medicine</i> , 2020, 21, 617-624.	2.2	115
28	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction—A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 227-232.	2.1	13
29	HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. <i>Viruses</i> , 2020, 12, 1241.	3.3	3
30	New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals. <i>Human Immunology</i> , 2020, 81, 300-304.	2.4	19
31	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 224, 1198-1208.	4.0	5
32	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.	4.0	22
33	Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment. <i>HIV Medicine</i> , 2020, 21, 599-606.	2.2	9
34	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 240-250.	2.1	24
35	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2019, 68, 569-576.	5.8	30
36	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. <i>Nature Communications</i> , 2019, 10, 3193.	12.8	112

#	ARTICLE	IF	CITATIONS
37	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 834.	2.9	6
38	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	13.7	627
39	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. <i>Journal of Infectious Diseases</i> , 2019, 220, 244-253.	4.0	6
40	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. <i>Journal of Infectious Diseases</i> , 2019, 220, 254-265.	4.0	27
41	Clusters of Sexual Behavior in Human Immunodeficiency Virusâ€“positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. <i>Clinical Infectious Diseases</i> , 2019, 70, 416-424.	5.8	9
42	Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. <i>Journal of Hepatology</i> , 2019, 71, 274-280.	3.7	31
43	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. <i>Journal of Infectious Diseases</i> , 2019, 220, 91-99.	4.0	24
44	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2019, 68, 561-568.	5.8	13
45	Imaging patterns of <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive and renal transplant patients â€“ a multicentre study. <i>Swiss Medical Weekly</i> , 2019, 149, w20130.	1.6	5
46	Highlights of the 2017 European <sc>AIDS</sc> Clinical Society (EACS) Guidelines for the treatment of adult <sc>HIV</sc>-positive persons version 9.0. <i>HIV Medicine</i> , 2018, 19, 309-315.	2.2	77
47	Fewer pills do not mean fewer drugâ€“drug interactions. <i>Aids</i> , 2018, 32, 676-678.	2.2	4
48	Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men. <i>HIV Medicine</i> , 2018, 19, 420-425.	2.2	12
49	Linkage and retention in <sc>HCV</sc> care for <sc>HIV</sc>-infected populations: early data from the <sc>DAA</sc> era. <i>Journal of the International AIDS Society</i> , 2018, 21, e25051.	3.0	40
50	No Effect of Pegylated Interferon-Î± on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2018, 217, 1883-1888.	4.0	10
51	Intestinal colonisation with extended-spectrum cephalosporin-resistant Enterobacteriaceae in different populations in Switzerland: prevalence, risk factors and molecular features. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 12, 17-19.	2.2	11
52	On the potential of a shortâ€“term intensive intervention to interrupt HCV transmission in HIVâ€“positive men who have sex with men: A mathematical modelling study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 10-18.	2.0	20
53	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. <i>Virus Evolution</i> , 2018, 4, vey024.	4.9	17
54	Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy275.	0.9	5

#	ARTICLE	IF	CITATIONS
55	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. <i>Molecular Biology and Evolution</i> , 2018, 35, 27-37.	8.9	37
56	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018, 561, 406-410.	27.8	47
57	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018, 32, 1995-2004.	2.2	24
58	Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 395-405.	5.1	15
59	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy078.	0.9	8
60	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	8.5	29
61	Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland. <i>HIV Medicine</i> , 2018, 19, 688-697.	2.2	6
62	Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy154.	0.9	17
63	Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome. <i>Scientific Reports</i> , 2018, 8, 7224.	3.3	16
64	Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. <i>Liver International</i> , 2018, 38, 424-431.	3.9	22
65	Hepatitis C Virus Infection and HIV. , 2018, , 625-633.		0
66	Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw809.	5.8	34
67	Intestinal colonisation with extended-spectrum cephalosporin- and colistin-resistant Enterobacteriaceae in HIV-positive individuals in Switzerland: molecular features and risk factors. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 519-521.	2.5	9
68	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1275-1278.	5.8	23
69	Recurrent Inflammatory Flares in HIV-Infected Patients: Consider Castleman Disease!. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2017, 5, 232470961772509.	0.6	0
70	A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure. <i>BMC Infectious Diseases</i> , 2017, 17, 81.	2.9	20
71	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017, 66, 297-303.	3.7	101
72	Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. <i>Swiss Medical Weekly</i> , 2017, 147, w14543.	1.6	12

#	ARTICLE	IF	CITATIONS
73	Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa. <i>Journal of the International AIDS Society</i> , 2016, 19, 20711.	3.0	19
74	Clinical Course, Radiological Manifestations, and Outcome of <i>Pneumocystis jirovecii</i> Pneumonia in HIV Patients and Renal Transplant Recipients. <i>PLoS ONE</i> , 2016, 11, e0164320.	2.5	23
75	Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient. <i>Aids</i> , 2016, 30, 530-533.	2.2	2
76	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016, 22, 1260-1267.	30.7	133
77	Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. <i>Hepatology</i> , 2016, 64, 1856-1869.	7.3	82
78	Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. <i>International Journal of Infectious Diseases</i> , 2016, 51, 97-102.	3.3	18
79	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 821-829.	5.8	48
80	Viral Escape in the Central Nervous System with Multidrug-Resistant Human Immunodeficiency Virus-1. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv210.	0.9	8
81	Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfecting men who have sex with men. <i>Journal of Hepatology</i> , 2016, 65, 26-32.	3.7	26
82	Heterogeneity in testing practices for infections during pregnancy: national survey across Switzerland. <i>Swiss Medical Weekly</i> , 2016, 146, w14325.	1.6	4
83	Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland. <i>Journal of Virus Eradication</i> , 2016, 2, 52-4.	0.5	12
84	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. <i>Antiviral Therapy</i> , 2015, 20, 261-269.	1.0	5
85	Impact of IL28B Genotype on First-Week Response to Telaprevir-Based Therapy in HIV-HCV Coinfection. <i>Antiviral Therapy</i> , 2015, 20, 407-413.	1.0	0
86	Molecular Analyses Define $\sim 7.2\text{-}133+$ MAIT Cell Depletion in HIV Infection. <i>Medicine (United States)</i> , 2015, 94, e1134.	1.0	23
87	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv108.	0.9	38
88	Protease inhibitors to treat hepatitis C in the Swiss HIV C cohort study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015, 16, 599-607.	2.2	5
89	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. <i>PLoS ONE</i> , 2015, 10, e0133028.	2.5	18
90	Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. <i>PLoS ONE</i> , 2015, 10, e0138838.	2.5	38

#	ARTICLE	IF	CITATIONS
91	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv026.	0.9	20
92	High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. <i>Journal of Hepatology</i> , 2015, 63, 573-580.	3.7	46
93	Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. <i>Gut</i> , 2015, 64, 813-819.	12.1	65
94	Hepatitis B viral load in dried blood spots: A validation study in Zambia. <i>Journal of Clinical Virology</i> , 2015, 72, 20-24.	3.1	25
95	Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0133879.	2.5	5
96	Hepatitis C: a changing epidemic. <i>Swiss Medical Weekly</i> , 2015, 145, w14093.	1.6	32
97	Hepatitis C Virus Infection and HIV. , 2015, , 1-9.		0
98	Changes in Biomarkers of Liver Disease during Successful Combination Antiretroviral Therapy in HIV/HCV-Coinfected Individuals. <i>Antiviral Therapy</i> , 2014, 19, 149-159.	1.0	11
99	Role of MicroRNA Modulation in the Interferon- λ /Ribavirin Suppression of HIV-1 In Vivo. <i>PLoS ONE</i> , 2014, 9, e109220.	2.5	7
100	Viral escape in the CNS with multidrug-resistant HIV-1. <i>Journal of the International AIDS Society</i> , 2014, 17, 19745.	3.0	15
101	Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. <i>HIV Medicine</i> , 2014, 15, 625-630.	2.2	13
102	Disentangling Human Tolerance and Resistance Against HIV. <i>PLoS Biology</i> , 2014, 12, e1001951.	5.6	53
103	Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. <i>Aids</i> , 2014, 28, 1261-1272.	2.2	18
104	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014, 43, 887-896.	1.9	36
105	Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 763-767.	3.4	29
106	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. <i>Journal of Infectious Diseases</i> , 2014, 210, 1555-1561.	4.0	16
107	Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland. <i>American Journal of Epidemiology</i> , 2014, 179, 1514-1525.	3.4	25
108	HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope. <i>Journal of Hepatology</i> , 2014, 60, 22-29.	3.7	24

#	ARTICLE	IF	CITATIONS
109	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. <i>Clinical Infectious Diseases</i> , 2013, 57, 112-121.	5.8	56
110	Expansion of interferon- γ -secreting HIV-specific T cells during successful antiretroviral therapy. <i>HIV Medicine</i> , 2013, 14, 241-246.	2.2	5
111	HLA-B*57:01+ abacavir-naive individuals have specific T cells but no patch test reactivity. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 756-758.	2.9	22
112	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3147-3158.	3.2	22
113	Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2013, 208, 1454-1458.	4.0	67
114	Early and nonreversible decrease of CD161 ⁺ /MAIT cells in HIV infection. <i>Blood</i> , 2013, 121, 951-961.	1.4	307
115	A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. <i>Journal of Mass Spectrometry</i> , 2013, 48, 616-625.	1.6	45
116	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283.	2.5	25
117	Low Levels of Mannan-Binding Lectin or Ficolins Are Not Associated with an Increased Risk of Cytomegalovirus Disease in HIV-Infected Patients. <i>PLoS ONE</i> , 2013, 8, e51983.	2.5	8
118	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. <i>ELife</i> , 2013, 2, e01123.	6.0	126
119	Parvovirus 4 Infection and Clinical Outcome in High-Risk Populations. <i>Journal of Infectious Diseases</i> , 2012, 205, 1816-1820.	4.0	34
120	Quantitative PCR to diagnose <i>Pneumocystis</i> pneumonia in immunocompromised non-HIV patients. <i>European Respiratory Journal</i> , 2012, 39, 971-978.	6.7	84
121	Role of retroviral restriction factors in the interferon- λ -mediated suppression of HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3035-3040.	7.1	129
122	Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. <i>Clinical Infectious Diseases</i> , 2012, 55, 1408-1416.	5.8	225
123	Effect of Hepatitis C Treatment on Cd4 ⁺ T-C El L Counts And The Risk Of Death In HIV-HCV-Coinfected Patients: The Cohere Collaboration. <i>Antiviral Therapy</i> , 2012, 17, 1541-1550.	1.0	7
124	Genetic Variations in IL28B and Allergic Disease in Children. <i>PLoS ONE</i> , 2012, 7, e30607.	2.5	23
125	HLA-B*57:01 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption. <i>HIV Medicine</i> , 2012, 13, 589-595.	2.2	2
126	Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis. <i>AIDS and Behavior</i> , 2012, 16, 245-255.	2.7	20

#	ARTICLE	IF	CITATIONS
127	Impact of a Nurse Vaccination Program on Hepatitis B Immunity in a Swiss HIV Clinic. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 472-474.	2.1	4
128	A randomized crossover study to compare efavirenz and etravirine treatment. <i>Aids</i> , 2011, 25, 57-63.	2.2	34
129	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. <i>Antiviral Therapy</i> , 2011, 16, 535-545.	1.0	77
130	A Bayesian network approach to study host and viral genetic correlates of HIV-1 disease progression. <i>Retrovirology</i> , 2011, 8, .	2.0	1
131	Effect of immune pressure on hepatitis C virus evolution: Insights from a single-source outbreak. <i>Hepatology</i> , 2011, 53, 396-405.	7.3	60
132	Estimating the net contribution of interleukinâ€28B variation to spontaneous hepatitis C virus clearance. <i>Hepatology</i> , 2011, 53, 1446-1454.	7.3	56
133	Personalized hepatitis C therapy: opportunities and pitfalls. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 127-129.	3.1	2
134	A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). <i>Aids</i> , 2011, 25, 1481-1487.	2.2	55
135	Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. <i>Aids</i> , 2011, 25, 2306-2308.	2.2	5
136	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. <i>Clinical Infectious Diseases</i> , 2011, 53, 1143-1152.	5.8	53
137	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	5.8	127
138	Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. <i>Aids</i> , 2011, 25, 399-409.	2.2	126
139	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. <i>Journal of Clinical Investigation</i> , 2011, 121, 2391-2400.	8.2	168
140	Constrained Pattern of Viral Evolution in Acute and Early HCV Infection Limits Viral Plasticity. <i>PLoS ONE</i> , 2011, 6, e16797.	2.5	21
141	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. <i>PLoS ONE</i> , 2011, 6, e27463.	2.5	46
142	The recent breakthroughs in the understanding of host genomics in hepatitis C. <i>European Journal of Clinical Investigation</i> , 2010, 40, 950-959.	3.4	28
143	Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression. <i>PLoS ONE</i> , 2010, 5, e11079.	2.5	78
144	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. <i>Gut</i> , 2010, 59, 1252-1258.	12.1	46

#	ARTICLE	IF	CITATIONS
145	Infrequent Replication of Parvovirus B19 and Erythrovirus Genotypes 2 and 3 among HIV-Infected Patients with Chronic Anemia. <i>Clinical Infectious Diseases</i> , 2010, 50, 115-118.	5.8	12
146	Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV-Infected Persons without Hepatitis B or C Virus Co-infection. <i>Clinical Infectious Diseases</i> , 2010, 50, 502-511.	5.8	88
147	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. <i>PLoS Pathogens</i> , 2010, 6, e1001123.	4.7	108
148	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. <i>Gastroenterology</i> , 2010, 138, 1338-1345.e7.	1.3	1,056
149	Effects of HIV type-1 immune selection on susceptibility to integrase inhibitor resistance. <i>Antiviral Therapy</i> , 2009, 14, 953-964.	1.0	4
150	CD4 ⁺ T Cell Count Decreases by Ethnicity among Untreated Patients with HIV Infection in South Africa and Switzerland. <i>Journal of Infectious Diseases</i> , 2009, 200, 1729-1735.	4.0	30
151	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. <i>Hepatology</i> , 2009, 49, 1069-1082.	7.3	131
152	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009, 50, 1017-1029.	7.3	60
153	How reliable is an undetectable viral load?. <i>HIV Medicine</i> , 2009, 10, 470-476.	2.2	9
154	Host genetic determinants of spontaneous hepatitis C clearance. <i>Pharmacogenomics</i> , 2009, 10, 1819-1837.	1.3	64
155	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. <i>Aids</i> , 2009, 23, 1689-1699.	2.2	69
156	The HCP5 Single Nucleotide Polymorphism: A Simple Screening Tool for Prediction of Hypersensitivity Reaction to Abacavir. <i>Journal of Infectious Diseases</i> , 2008, 198, 864-867.	4.0	90
157	Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, 1921-1925.	5.8	28
158	Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. <i>Aids</i> , 2008, 22, 2135-2141.	2.2	145
159	Low current and nadir CD4 ⁺ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. <i>Antiviral Therapy</i> , 2008, 13, 455-60.	1.0	7
160	Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 1019-28.	1.0	7
161	Low Current and Nadir CD4 ⁺ T-Cell Counts are Associated with Higher Hepatitis C virus RNA Levels in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 455-460.	1.0	15
162	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 1019-1028.	1.0	29

#	ARTICLE	IF	CITATIONS
163	[784] EXHAUSTION OF VIRUS SPECIFIC CD4+ T CELLS DURING ACUTE HEPATITIS C. Journal of Hepatology, 2007, 46, S295.	3.7	0
164	Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens, 2007, 69, 237-240.	1.0	45
165	Tracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus Infection. PLoS ONE, 2007, 2, e649.	2.5	65
166	Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study. Clinical Infectious Diseases, 2006, 43, 99-102.	5.8	301
167	Dysphagia in Elderly Women: Consider Tetanus. Infection, 2006, 34, 35-38.	4.7	9
168	Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics, 2006, 7, 15-23.	1.3	20
169	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. Journal of Virology, 2006, 80, 11094-11104.	3.4	103
170	Unsafe Sex and Increased Incidence of Hepatitis C Virus Infection among HIV-Infected Men Who Have Sex with Men: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2005, 41, 395-402.	5.8	203
171	Chronic Hepatitis C in HIV-Infected Patients: Low Eligibility and Applicability of Therapy With Pegylated Interferon-?? Plus Ribavirin. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 238-240.	2.1	41